TABLE 1.
Baseline demographic and clinical characteristics
| Characteristic | Previous efavirenz regimen (n = 114) | Other previous regimen (n = 556)a |
|---|---|---|
| Age (median [range]) (yr) | 46 (24–71) | 42 (21–71) |
| Male (no. [%]) | 98 (86.0) | 468 (84.2) |
| Race/ethnicity (no. [%]) | ||
| White | 78 (68.4) | 434 (78.1) |
| Black or African American | 18 (15.8) | 72 (12.9) |
| Asian | 7 (6.1) | 18 (3.2) |
| Multiracial | 6 (5.3) | 29 (5.2) |
| Other raceb | 5 (4.4) | 3 (0.5) |
| Hispanic or Latino | 34 (29.8) | 110 (19.8) |
| Region (no. [%]) | ||
| Asia/Pacific region | 13 (11.4) | 18 (3.2) |
| Europe | 52 (45.6) | 353 (63.5) |
| Latin America | 18 (15.8) | 55 (9.9) |
| North America | 31 (27.2) | 130 (23.4) |
| CD4+ T-cell count | ||
| Median (range) (cells/mm3) | 633 (184–1711) | 626.5 (82–1928) |
| No. (%) with <200 cells/mm3 | 1 (0.9) | 16 (2.9) |
| No. (%) with ≥200 cells/mm3 | 112 (98.2) | 530 (95.3) |
| Duration of prior regimen | ||
| Median (range) (mo) | 65.1 (7.0–264.9) | 46.9 (6.9–217.6) |
| No. (%) with duration of ≥12 mo | 107 (93.9) | 525 (94.4) |
| History of AIDS (no. [%]) | 20 (17.5) | 95 (17.1) |
| Hepatitis B and/or C positive (no. [%]) | 3 (2.6) | 20 (3.6) |
a
Other previous regimens included two NRTIs with nevirapine, rilpivirine, boosted elvitegravir, or a boosted protease inhibitor (atazanavir, darunavir, or lopinavir).
b
Other race included American Indian and Alaska Native.